The historical rank and industry rank for Esperion Therapeutics's Equity-to-Asset or its related term are showing as below:
ESPR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.21 Med: 0.49 Max: 0.97
Current: -0.79
During the past 13 years, the highest Equity to Asset Ratio of Esperion Therapeutics was 0.97. The lowest was -2.21. And the median was 0.49.
ESPR's Equity-to-Asset is ranked worse than 93.46% of 1085
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs ESPR: -0.79
Esperion Therapeutics Equity-to-Asset Historical Data
The historical data trend for Esperion Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Esperion Therapeutics's Equity-to-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Equity-to-Asset falls into.
Esperion Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Esperion Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Esperion Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Esperion Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Esperion Therapeutics (Esperion Therapeutics) Business Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ESPR has been successfully added to your 